These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9506001)

  • 21. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
    Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
    Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
    McTavish D; Sorkin EM
    Drugs; 1989 Nov; 38(5):778-800. PubMed ID: 2574665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram.
    Gutierrez M; Abramowitz W
    Pharmacotherapy; 2001 Feb; 21(2):163-8. PubMed ID: 11213852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose related protective effect of azelastine on histamine induced bronchoconstriction in extrinsic asthma.
    Bauer K; Aurich R; Kaik G
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):333-8. PubMed ID: 1980266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis.
    Lieberman PL; Settipane RA
    Allergy Asthma Proc; 2003; 24(2):95-105. PubMed ID: 12776442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
    J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study.
    Boyce MJ; Baisley KJ; Warrington SJ
    Br J Clin Pharmacol; 2012 Mar; 73(3):411-21. PubMed ID: 21883386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity.
    Gras J; Llenas J; Palacios JM; Roberts DJ
    Br J Pharmacol; 1996 Sep; 119(2):187-8. PubMed ID: 8886395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
    Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
    Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.
    Miceli JJ; Smith M; Robarge L; Morse T; Laurent A
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):71S-76S. PubMed ID: 10771458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of allergic histamine release from rat peritoneal mast cells by azelastine. Interaction with selected antiasthmatic drugs.
    Chand N; Pillar J; Diamantis W; Sofia RD
    Int Arch Allergy Appl Immunol; 1988; 86(3):256-60. PubMed ID: 2456990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability, pharmacokinetics and dose linearity of azelastine hydrochloride in healthy subjects.
    Riethmüller-Winzen H; Peter G; Büker KM; Romeis P; Borbe HO
    Arzneimittelforschung; 1994 Oct; 44(10):1136-40. PubMed ID: 7818588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibitory effect of azelastine and ketotifen on histamine-induced bronchoconstriction in asthmatic patients.
    Magnussen H
    Chest; 1987 Jun; 91(6):855-8. PubMed ID: 2884081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of irinotecan metabolism by ketoconazole.
    Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
    J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.